UNASSIGNED: @entity73 ( @entity73 ) is frequent in @entity191 ( @entity1726 ). Recently proposed criteria for @entity73 in @entity1726 ( @entity1726 ) indicate level I diagnosis based on abbreviated assessment and level II based on comprehensive neuropsychological evaluation. The study explored the sensitivity and specificity of the Italian versions of three neuropsychological tests for level I diagnosis of @entity1726 . We recruited 100 consecutive @entity1726 @entity1 . After screening for inclusion criteria, 43 @entity1 were included. The sensitivity and specificity of the Mini Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), and the Addenbrooke's Cognitive Examination Revised (ACE-R) in comparison to level II diagnosis of @entity1726 were examined. @entity1726 was diagnosed (level II) in 51% of @entity1 . Disease duration was significantly longer and @entity1726 motor scales were more severely impaired in @entity73 group. The receiver-operator characteristics curve documented nonsignificant difference in the performance of the three tests, with slight advantage of MMSE (corrected data). The time of administration favored MMSE. In Italian-speaking @entity1726 @entity1 , MMSE might represent a good screening tool for @entity1726 , because of the shorter time of administration and the performance comparable to those of MoCA and ACE-R. Further studies are needed to validate the new @entity1726 criteria across different languages and cultures.

Screening for Mild XXXX in @entity191 : Comparison of the Italian Versions of Three Neuropsychological Tests.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity73 :: ('MESH:D003072', 'Disease') :: ['Mild cognitive impairment', 'MCI'] @entity1726 :: ('OMIM:168600', 'Disease') :: ['PD-MCI', 'PD'] @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease"]
@entity73 :: (MESH:D003072,Disease) :: ['Cognitive Impairment']
